Acquisition of 35.85% Stake in BioVille for 12.4 Billion Won via Litigation Settlement
- Decision to acquire 5,509,953 shares (35.85%) of BioVille for 12.4 billion won as a result of litigation settlement
- Payment in cash (3.5 billion won from escrow) and 15th convertible bonds (8.9 billion won)
- BioVille had zero revenue and a net loss of 1.268 billion won in 2025
- After acquisition, Korea Stem Cell Bank's stake in BioVille increases to 35.85%
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Decision on Acquisition of Stocks and Investment Securities of Other Corporations
- Company: GemVax & KAEL (082270)
- Submission: GemVax & KAEL Co.,Ltd.
- Receipt: 04-28-2026
- Under KRX KOSDAQ Market Division